Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024, both virtually and in-person at the Lotte New York Palace Hotel in New York, NY.
Key details of Apollomics' participation include:
- An on-demand company presentation available from September 9, 2024, at 7:00 am ET
- Presenters: Guo-Liang Yu, PhD (Chairman and CEO) and Matthew Plunkett, PhD (CFO)
- Management will be available for virtual one-on-one meetings
- The presentation will be accessible on the company's website
Apollomics focuses on developing oncology drug candidates for difficult-to-treat and treatment-resistant cancers.
Apollomics Inc. (Nasdaq: APLM), un'azienda biopharmaceutica clinica in fase avanzata, ha annunciato la sua partecipazione alla 26ª Conferenza Globale di Investimenti Annuale H.C. Wainwright. L'evento si terrà dal 9 all'11 settembre 2024, sia virtualmente che di persona presso il Lotte New York Palace Hotel a New York, NY.
I dettagli chiave della partecipazione di Apollomics includono:
- Una presentazione aziendale on-demand disponibile dal 9 settembre 2024, alle 7:00 ET
- Relatori: Guo-Liang Yu, PhD (Presidente e CEO) e Matthew Plunkett, PhD (CFO)
- Il management sarà disponibile per incontri virtuali one-on-one
- La presentazione sarà accessibile sul sito web dell'azienda
Apollomics si concentra sullo sviluppo di candidati farmaceutici oncologici per tumori difficili da trattare e resistenti ai trattamenti.
Apollomics Inc. (Nasdaq: APLM), una compañía biofarmacéutica clínica en etapa avanzada, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El evento se llevará a cabo del 9 al 11 de septiembre de 2024, tanto de forma virtual como presencial en el Lotte New York Palace Hotel en Nueva York, NY.
Los detalles clave de la participación de Apollomics incluyen:
- Una presentación de la empresa bajo demanda disponible a partir del 9 de septiembre de 2024, a las 7:00 am ET
- Presentadores: Guo-Liang Yu, PhD (Presidente y CEO) y Matthew Plunkett, PhD (CFO)
- La dirección estará disponible para reuniones virtuales uno a uno
- La presentación estará accesible en el sitio web de la empresa
Apollomics se enfoca en desarrollar candidatos a medicamentos oncológicos para cánceres difíciles de tratar y resistentes a los tratamientos.
Apollomics Inc. (Nasdaq: APLM)는 후기 단계의 임상 바이오제약 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕 NY의 Lotte New York Palace Hotel에서 대면 및 가상으로 진행됩니다.
Apollomics의 참여와 관련된 주요 세부 사항은 다음과 같습니다:
- 2024년 9월 9일 오전 7시 ET부터 제공되는 주문형 회사 프레젠테이션
- 발표자: Guo-Liang Yu, PhD (회장 및 CEO) 및 Matthew Plunkett, PhD (CFO)
- 경영진이 가상 일대일 회의에 참석 가능
- 프레젠테이션은 회사 웹사이트에서 확인 가능
Apollomics는 치료하기 어렵고 치료 저항성이 있는 암을 위한 항암제 후보 개발에 집중하고 있습니다.
Apollomics Inc. (Nasdaq: APLM), une entreprise biopharmaceutique clinique en phase avancée, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement se déroulera du 9 au 11 septembre 2024, à la fois virtuellement et en personne au Lotte New York Palace Hotel à New York, NY.
Les détails clés de la participation d'Apollomics comprennent :
- Une présentation de l'entreprise à la demande, disponible à partir du 9 septembre 2024, à 7h00 ET
- Présentateurs : Guo-Liang Yu, PhD (Président et CEO) et Matthew Plunkett, PhD (CFO)
- La direction sera disponible pour des réunions virtuelles individuelles
- La présentation sera accessible sur le site internet de l'entreprise
Apollomics se concentre sur le développement de candidats médicaments en oncologie pour les cancers difficiles à traiter et résistants aux traitements.
Apollomics Inc. (Nasdaq: APLM), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 sowohl virtuell als auch in-person im Lotte New York Palace Hotel in New York, NY statt.
Wichtige Einzelheiten zur Teilnahme von Apollomics sind:
- Eine On-Demand-Unternehmenspräsentation, die ab 9. September 2024, 7:00 Uhr ET verfügbar ist
- Präsentatoren: Guo-Liang Yu, PhD (Vorsitzender und CEO) und Matthew Plunkett, PhD (CFO)
- Das Management steht für virtuelle Einzelgespräche zur Verfügung
- Die Präsentation wird auf der Unternehmenswebsite zugänglich sein
Apollomics konzentriert sich auf die Entwicklung von Onkologie-Arzneimittelkandidaten für schwer zu behandelnde und behandlungsresistente Krebserkrankungen.
- None.
- None.
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY.
H.C. Wainwright 26th Annual Global Investment Conference
Format: Company presentation
Presentation Date & Time: Available on demand as of September 9, 2024 at 7:00 am ET
Presenters: Guo-Liang Yu, PhD, Chairman and Chief Executive Officer and Matthew Plunkett, PhD, Chief Financial Officer
Webcast: Click here
Management will be available for virtual one-on-one meetings during the conference. Interested investors should contact their H.C. Wainwright representative to request meetings. The Company’s current presentation may be accessed on the Company website on the Events page under the Investors section.
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ programs include its lead product candidate, vebreltinib, a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort global clinical trial, and uproleselan, a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in a Phase 3 clinical trial in China. For more information, please visit www.apollomicsinc.com.
Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
(646) 751-4363
eric@lifesciadvisors.com
FAQ
When is Apollomics (APLM) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Apollomics (APLM) at the investment conference?
Where can investors access Apollomics' (APLM) presentation from the H.C. Wainwright conference?
What type of cancer treatments is Apollomics (APLM) developing?
Will Apollomics (APLM) management be available for meetings during the conference?
